{"id":"ldl-reduction-therapy","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Muscle pain"},{"rate":"1-5%","effect":"Liver enzyme elevation"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4298181","moleculeType":"Gene"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"LDL reduction therapy works by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver.","oneSentence":"HMG-CoA reductase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:41:54.411Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT07459504","phase":"PHASE2","title":"SMART Diets for MASLD","status":"NOT_YET_RECRUITING","sponsor":"Corewell Health West","startDate":"2026-04-26","conditions":"Metabolic-dysfunction Associated Steatotic Liver Disease","enrollment":102},{"nctId":"NCT07425093","phase":"NA","title":"Investigation of the Relationship Between Gray and White Matter Volumes, Walking Exercise, and Body Fat Percentage in Adults With a Body Mass Index Above 25","status":"COMPLETED","sponsor":"Amasya University","startDate":"2024-01-01","conditions":"Obesity & Overweight, Headache, Sedentary Lifestyle","enrollment":22},{"nctId":"NCT05844566","phase":"NA","title":"OptimiZation Of Lipid Lowering Therapies Using a Decision Support System In Patients With Acute Coronary Syndrome.","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2023-04-03","conditions":"Acute Coronary Syndrome, Myocardial Infarction","enrollment":1139},{"nctId":"NCT04861545","phase":"","title":"Meta-analyses of Soy Protein and Its Food Sources for Cholesterol Reduction","status":"ACTIVE_NOT_RECRUITING","sponsor":"John Sievenpiper","startDate":"2021-05-01","conditions":"Dyslipidemias, Cardiovascular Risk Factor, Dysglycemia","enrollment":1},{"nctId":"NCT07349875","phase":"PHASE4","title":"Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-01","conditions":"Coronary Artery Disease (CAD)","enrollment":3826},{"nctId":"NCT05462262","phase":"NA","title":"Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population","status":"ENROLLING_BY_INVITATION","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2022-10-10","conditions":"Coronary Artery Disease Progression","enrollment":2900},{"nctId":"NCT05641753","phase":"PHASE4","title":"Cholesterol Lowering and Residual Risk in Diabetes, Type 1","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-12-06","conditions":"Type 1 Diabetes","enrollment":125},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT06855537","phase":"PHASE4","title":"Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-11-03","conditions":"Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques, Thin-cap fIbroatheroma","enrollment":2190},{"nctId":"NCT07255820","phase":"PHASE4","title":"Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol","status":"NOT_YET_RECRUITING","sponsor":"Bahria University","startDate":"2026-01-01","conditions":"Type 2 Diabetes Mellitus, Hypercholesterolemia / Elevated LDL Cholesterol","enrollment":126},{"nctId":"NCT07252388","phase":"NA","title":"EARLY: Educational Intervention to Improve Patient Awareness on Early LDL-C Lowering in Secondary Prevention","status":"NOT_YET_RECRUITING","sponsor":"Heart Care Foundation","startDate":"2025-12-11","conditions":"Acute Coronary Syndromes, Chronic Coronary Syndromes","enrollment":240},{"nctId":"NCT04755413","phase":"NA","title":"The Precision CAD Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-10-19","conditions":"Coronary Artery Disease","enrollment":276},{"nctId":"NCT07242599","phase":"PHASE3","title":"Ongericimab Injection Reducing Recurrence of Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12","conditions":"Ischemic Cerebral Infarction","enrollment":4398},{"nctId":"NCT03722303","phase":"EARLY_PHASE1","title":"Lipografting Versus Steroid Injections for Treatment of Carpal Tunnel Syndrome","status":"SUSPENDED","sponsor":"Columbia University","startDate":"2016-12-19","conditions":"Carpal Tunnel Syndrome","enrollment":100},{"nctId":"NCT07178769","phase":"NA","title":"Study To Evaluate The Efficacy And Safety Of A Nutritional Supplement Based On Bergamot, Artichoke And Other Ingredients For Reducing Cholesterol Levels In Patients With Hypercholesterolemia (Metachol+)","status":"RECRUITING","sponsor":"Laboratoires Arkopharma","startDate":"2025-04-20","conditions":"Cholesterolemia","enrollment":207},{"nctId":"NCT05660135","phase":"","title":"Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-06-20","conditions":"Hypertension, Dyslipidemias","enrollment":4000},{"nctId":"NCT05988866","phase":"NA","title":"Effects of a Digital Health Application (Lipodia) on LDL-cholesterol Levels","status":"RECRUITING","sponsor":"Gaia AG","startDate":"2025-02-03","conditions":"Hypercholesterolemia, Dyslipidemias","enrollment":272},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT04992065","phase":"PHASE2","title":"A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-08-03","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":267},{"nctId":"NCT06338956","phase":"","title":"Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2024-01-01","conditions":"Coronary Artery Disease, Hyperlipidemias","enrollment":135877},{"nctId":"NCT06812221","phase":"PHASE1, PHASE2","title":"Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-12-15","conditions":"Mild Cognitive Impairment, Anxiety State, Depression Anxiety Disorder","enrollment":20},{"nctId":"NCT06816667","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety","status":"COMPLETED","sponsor":"Biomind Labs Inc.","startDate":"2024-10-21","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT05703126","phase":"NA","title":"Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML","status":"RECRUITING","sponsor":"Samara State Medical University","startDate":"2022-12-01","conditions":"Acute Myeloid Leukemia, Adult, Cardiotoxicity, Endothelial Dysfunction","enrollment":100},{"nctId":"NCT05004675","phase":"PHASE3","title":"Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2022-06-20","conditions":"Hypercholesterolemia, Atherosclerotic Ischemic Disease","enrollment":166},{"nctId":"NCT04798430","phase":"PHASE3","title":"Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction","status":"ENROLLING_BY_INVITATION","sponsor":"LIB Therapeutics LLC","startDate":"2020-12-03","conditions":"Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol, Familial Hypercholesterolemia","enrollment":2000},{"nctId":"NCT00708981","phase":"NA","title":"Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)","status":"COMPLETED","sponsor":"Cook County Health","startDate":"2007-05","conditions":"Diabetic Nephropathy","enrollment":120},{"nctId":"NCT00652717","phase":"PHASE4","title":"Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2005-02-01","conditions":"Cardiovascular Disorder","enrollment":280},{"nctId":"NCT04141579","phase":"NA","title":"Functional Improvement of Coronary Artery Narrowing by Cholesterol Reduction With a PCSK9 Antibody","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-11-10","conditions":"Coronary Artery Disease, Atherosclerosis of Coronary Artery","enrollment":150},{"nctId":"NCT06448234","phase":"NA","title":"Evaluating the Efficacy of AI-Guided (GenAIS TM) vs. Standard Physician-Guided Dietary Supplement Prescriptions for Lowering LDL Cholesterol in Hypercholesterolemic Patients","status":"COMPLETED","sponsor":"S.LAB (SOLOWAYS)","startDate":"2024-02-02","conditions":"Hypercholesterolemia","enrollment":70},{"nctId":"NCT02624869","phase":"PHASE3","title":"Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-09-10","conditions":"Familial Hypercholesterolemia","enrollment":163},{"nctId":"NCT01764633","phase":"PHASE3","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-08","conditions":"Dyslipidemia","enrollment":27564},{"nctId":"NCT06381947","phase":"PHASE4","title":"Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Salerno","startDate":"2024-05-01","conditions":"Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT06196398","phase":"","title":"Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2023-01-01","conditions":"Stroke, Ischemic, Intracranial Atherosclerosis","enrollment":400},{"nctId":"NCT04964557","phase":"PHASE2","title":"A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-07-07","conditions":"Hyperlipidaemia","enrollment":411},{"nctId":"NCT04806893","phase":"PHASE3","title":"Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction","status":"UNKNOWN","sponsor":"LIB Therapeutics LLC","startDate":"2021-04-22","conditions":"Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke","enrollment":900},{"nctId":"NCT04797104","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2021-04-22","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":478},{"nctId":"NCT04797247","phase":"PHASE3","title":"Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction","status":"UNKNOWN","sponsor":"LIB Therapeutics LLC","startDate":"2021-04-22","conditions":"Cardiovascular Diseases, Hyper-LDL-cholesterolemia","enrollment":900},{"nctId":"NCT04347434","phase":"PHASE4","title":"Assessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI","status":"RECRUITING","sponsor":"Penza State University","startDate":"2020-02-12","conditions":"Myocardial Infarction, Acute, Myocardial Strain, Arterial Stiffness","enrollment":300},{"nctId":"NCT00810979","phase":"PHASE2","title":"Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Response Pharmaceuticals","startDate":"2009-01","conditions":"Hyperlipidemia","enrollment":133},{"nctId":"NCT05765370","phase":"NA","title":"LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-03-24","conditions":"Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol","enrollment":4200},{"nctId":"NCT04790513","phase":"PHASE3","title":"Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2021-04-22","conditions":"Hypercholesterolemia, Cardiovascular Diseases","enrollment":204},{"nctId":"NCT03960541","phase":"PHASE2","title":"Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)","status":"TERMINATED","sponsor":"Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2020-08-31","conditions":"HIV Infections, Dyslipidemias","enrollment":8},{"nctId":"NCT04641299","phase":"PHASE2","title":"A Study of AZD8233 in Participants With Dyslipidemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-28","conditions":"Dyslipidaemia","enrollment":119},{"nctId":"NCT02392559","phase":"PHASE3","title":"Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-03-24","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":158},{"nctId":"NCT03233243","phase":"PHASE4","title":"Rosuvastatin Effect on Atherosclerotic Plaque Metabolism","status":"COMPLETED","sponsor":"University of Coimbra","startDate":"2020-07-27","conditions":"Cardiovascular Diseases, Atherosclerosis, Molecular Imaging","enrollment":40},{"nctId":"NCT05483192","phase":"NA","title":"Impact of Oral Dyglomera™ on Body Fat and Blood Lipids of Overweight and Obese Adults","status":"COMPLETED","sponsor":"Gateway Health Alliance","startDate":"2021-02-12","conditions":"Body Fat Disorder","enrollment":120},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT05267990","phase":"NA","title":"Coronary Artery Calcium-guided Primary Prevention of Major Coronary Heart Disease in Asymptomatic Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"JuFeng, Hsiao","startDate":"2022-03-01","conditions":"Type2 Diabetes, Coronary Heart Disease","enrollment":2000},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT04783714","phase":"NA","title":"Investigating Effects of a Novel Nutraceutical on Hypercholesterolaemia in Australian Adults","status":"COMPLETED","sponsor":"Swisse Wellness Pty Ltd","startDate":"2021-04-30","conditions":"Hypercholesterolemia","enrollment":42},{"nctId":"NCT03847974","phase":"PHASE2","title":"Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2019-02-14","conditions":"Hypercholesterolemia","enrollment":32},{"nctId":"NCT05214872","phase":"","title":"The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Poznan University of Medical Sciences","startDate":"2016-03-25","conditions":"Atherosclerosis of Artery, Inflammation, Chronic Kidney Diseases","enrollment":252},{"nctId":"NCT05081336","phase":"","title":"Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry","status":"UNKNOWN","sponsor":"University Clinical Centre of Republic of Srpska","startDate":"2021-03-01","conditions":"Acute Coronary Syndrome, Dyslipidemias","enrollment":500},{"nctId":"NCT02965911","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA","status":"WITHDRAWN","sponsor":"Beijing 302 Hospital","startDate":"2016-01","conditions":"Primary Biliary Cirrhosis","enrollment":""},{"nctId":"NCT04147767","phase":"NA","title":"Plant Sterol INtervention for Cancer Prevention (PINC)","status":"UNKNOWN","sponsor":"University of Leeds","startDate":"2020-02-10","conditions":"Hypercholesterolemia, Breast Cancer, Obesity","enrollment":50},{"nctId":"NCT04087915","phase":"","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2019-09-11","conditions":"Dyslipidemia, High Risk Coronary Artery Disease","enrollment":1000},{"nctId":"NCT01106495","phase":"NA","title":"Effect of Enhanced External Counterpulsation (EECP) on Subclinical Atherosclerosis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-05","conditions":"Atherosclerosis","enrollment":150},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":"Diabetic Nephropathy","enrollment":850},{"nctId":"NCT01741428","phase":"NA","title":"\"Hjerteloeftet\" (\"HeartLift\"). Interaction For Preventing Cardiovascular Disease","status":"COMPLETED","sponsor":"LHL Helse","startDate":"2012-11","conditions":"Cardiovascular Disease","enrollment":701},{"nctId":"NCT02347098","phase":"PHASE3","title":"Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2015-03-30","conditions":"Acute Coronary Artery Syndrome","enrollment":270},{"nctId":"NCT00965055","phase":"PHASE3","title":"Ezetimibe in Patients Hypo-responsive to Statins","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2009-09","conditions":"High Cholesterol, Coronary Artery Disease","enrollment":2},{"nctId":"NCT03971019","phase":"PHASE3","title":"Survival Benefits of Statins in Breast Cancer Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-03-28","conditions":"Breast Cancer Female","enrollment":314},{"nctId":"NCT01004406","phase":"PHASE3","title":"Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-09","conditions":"Acute Coronary Syndrome","enrollment":59},{"nctId":"NCT01586702","phase":"NA","title":"Intensified Secondary Prevention Intending a Reduction of Recurrent Events in TIA and Minor Stroke Patients","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-09","conditions":"Mini-Stroke","enrollment":2082},{"nctId":"NCT01483560","phase":"PHASE3","title":"REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)","status":"COMPLETED","sponsor":"University of Glasgow","startDate":"2011-12","conditions":"Diabetes Mellitus, Type 1","enrollment":493},{"nctId":"NCT01763918","phase":"PHASE3","title":"Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-07","conditions":"Hyperlipidemia","enrollment":331},{"nctId":"NCT03549260","phase":"PHASE2","title":"Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction","status":"COMPLETED","sponsor":"LIB Therapeutics LLC","startDate":"2018-05-22","conditions":"LDL Cholesterol","enrollment":81},{"nctId":"NCT01420016","phase":"NA","title":"Prioritized Clinical Decision Support (CDS) to Reduce Cardiovascular Risk","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2012-08-20","conditions":"Hypertension, Hyperlipidemia, Diabetes","enrollment":7914},{"nctId":"NCT00526058","phase":"NA","title":"(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol","status":"COMPLETED","sponsor":"B. Braun Medical Inc.","startDate":"2007-08","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT00300976","phase":"NA","title":"The Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases","status":"UNKNOWN","sponsor":"Japan Foundation for the Promotion of International Medical Research Cooperation","startDate":"2006-05","conditions":"Cardiovascular Diseases, Diabetes Mellitus, Type 2","enrollment":2542},{"nctId":"NCT03152396","phase":"NA","title":"Pharmacist CVD Intervention for Patients With Inflammatory Arthritis","status":"UNKNOWN","sponsor":"Epidemiology Coordinating and Research Centre, Canada","startDate":"2017-07-17","conditions":"Inflammatory Arthritis, Cardiovascular Risk Factor, Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT03203486","phase":"NA","title":"Response of NAFLD Patients to Mediterranean Diet","status":"COMPLETED","sponsor":"Harokopio University","startDate":"2014-04","conditions":"NAFLD, Steatosis of Liver","enrollment":44},{"nctId":"NCT01953328","phase":"PHASE3","title":"Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-10","conditions":"Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events","enrollment":409},{"nctId":"NCT02548936","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2015-04","conditions":"Atherosclerosis","enrollment":30},{"nctId":"NCT01064934","phase":"NA","title":"Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a)","status":"WITHDRAWN","sponsor":"Charite University, Berlin, Germany","startDate":"2010-09","conditions":"Hyperlipoproteinemia(a), Progressive Cardiovascular Disease","enrollment":""},{"nctId":"NCT02269046","phase":"NA","title":"Acupuncture and Moxibustion for Hyperlipemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine","startDate":"2014-12","conditions":"Hyperlipidemias","enrollment":210},{"nctId":"NCT00920101","phase":"PHASE4","title":"Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging","status":"UNKNOWN","sponsor":"National Defense Medical College, Japan","startDate":"2009-06","conditions":"Atherosclerosis, Inflammation","enrollment":30},{"nctId":"NCT01628705","phase":"PHASE4","title":"Moderated-fat Diet Complemented With Green Tea Reduces oxLDL and Fat Mass in Obese Women","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2007-04","conditions":"Nutritional and Metabolic Disease","enrollment":64},{"nctId":"NCT00397657","phase":"PHASE4","title":"Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis","status":"TERMINATED","sponsor":"Walter Reed Army Medical Center","startDate":"2006-11","conditions":"Atherosclerosis","enrollment":400},{"nctId":"NCT00734123","phase":"PHASE4","title":"Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases.","status":"UNKNOWN","sponsor":"Hospital Arnau de Vilanova","startDate":"2008-04","conditions":"Atherosclerosis, Cardiovascular Diseases","enrollment":2948}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"LDL reduction therapy","genericName":"LDL reduction therapy","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HMG-CoA reductase inhibitor Used for Hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}